Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab, formerly known as Numax(R), is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its first pivotal trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated a 26-percent reduction in RSV hospitalizations due to RSV and a 50-percent reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, its secondary endpoint.

About Synagis

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RS
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014  Cardica, Inc. ... the Cardica Board has approved management,s recommendation to ... launch of the MicroCutter XCHANGE® 30 surgical stapler ... commercial launch.  As a result, Cardica has temporarily ... withdrawing its latest iteration of the MicroCutter XCHANGE ...
(Date:11/18/2014)... LAVAL, Quebec , Nov. 18, 2014  Valeant ... VRX) and Ideal Implant Incorporated today announced the receipt ... (FDA) and Health Canada to market the IDEAL IMPLANT ... in primary breast augmentation or replacement of existing augmentation ... based on an extensive review of various studies and ...
(Date:11/17/2014)... , Nov. 17, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... at the Canaccord Genuity 2014 Medical Technology & Diagnostics ... the Westin Grand Central on Thursday, November 20 at ... will present a general overview of the Company,s current ...
Breaking Medicine Technology:Cardica Announces Shift In Focus 2Cardica Announces Shift In Focus 3Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2
(Date:11/18/2014)... November 18, 2014 Medicationdiscountcard.com's ... insights, adding to the company's reputation for helping ... the blog has to offer at http://blog.medicationdiscountcard.com/ ... the information concerning the Affordable Care Act and ... to inform the public about a variety of ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... experimental antibody drug could prove effective at lowering LDL ... with cholesterol-lowering statin medications. That,s the conclusion of ... Association annual meeting in Chicago. The drug, alirocumab, ... widely used alternative to statins, Zetia, said lead researcher ...
(Date:11/18/2014)... News) -- Women who started smoking at a young ... menstrual pain, a new study suggests. About 29 ... has been suspected as a risk factor for severe ... of the new study said. The researchers analyzed ... study of women,s health in Australia. About 14 percent ...
(Date:11/18/2014)... 2014 Global Partnership for ... telehealth platform to bring quality healthcare to populations ... GPT created Global Partnership for TeleHealth Missions (GPTM), ... telehealth network. GPTM focuses specifically on medical ... disaster relief organizations. , Michael D’Ambrosio, ...
(Date:11/18/2014)... Beach, Virginia (PRWEB) November 18, 2014 ... experience frustrating situations with print devices like unforeseen error ... when they don't have time to find another printer ... the issue. The IT department is likely tied up ... familiar? , That’s where Electronic Systems, ...
Breaking Medicine News(10 mins):Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2
... CareMedic Systems ( http://www.caremedic.com ... patient financial data, has entered into an OEM agreement with ... ), for its Cincom Knowledge Master(R) software to ... , , Registration-based data-quality issues represent a significant source ...
... Researchers from the Kennedy Krieger Institute and Johns Hopkins ... new insights into the neurological basis of autism. Their ... , examined patterns of movement as children with autism ... tool. The findings suggest that children with autism appear ...
... Calif., July 6 Quest International, Inc. announced it was ... Global Supplier of the Year Award. This is the ... the award, receiving honors in 2006 as well. , ... Annual Supplier Conference. Quest was selected for their recognition ...
... could include microscopic beads that create "designer" immune cells ... of Georgia researchers say. "It,s absolutely natural," says ... for Molecular Chaperone/Radiobiology and Cancer Virology, who has used ... The degradable microparticles deliver the most powerful known form ...
... General Dynamics Information Technology, a business unit of General ... $9.2 million dollar, three-year contract to support the U.S. Army ... , General Dynamics will support the Army MEDCOM Lean ... consulting services to internal organizations for MEDCOM,s Director of Strategy ...
... Dick, Senior Scientist at the Ontario Cancer Institute, the ... team that has developed the first leukemia therapy that ... stem cells that drive acute myeloid leukemia (AML), which ... Dr. Richard Lock is leading the clinical trial ...
Cached Medicine News:Health News:CareMedic and Cincom Sign OEM Technology Partnership for Healthcare Solution 2Health News:New study pinpoints difference in the way children with autism learn new behaviors 2Health News:New study pinpoints difference in the way children with autism learn new behaviors 3Health News:Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 2Health News:Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 3Health News:Microscopic 'beads' could help create 'designer' immune cells that ignore transplanted organs 2Health News:General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support 2Health News:Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia 2
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... Fluorometer utilizes unique microprocessor-controlled filter wheels for ... optics. The filter wheels can be programmed ... of applications. With this fluorometer, you do ... or two wavelengths. The C&L Dye Fluorometer ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
... Designed to stabilize the capsular bag in ... rings are specially designed for scleral fixation ... the Cincinnati Eye Institute, recognized from his ... that there was a need for greater ...
Medicine Products: